Active Clinical Trials and Research Studies

Active

The study is designed to examine the safety and efficacy of a drug that targets the protein tau in the brains of people with Alzheimer’s disease. Research has shown that cognitive decline in patients with Alzheimer’s disease may relate to levels of abnormal tau protein in the brain.

 

More information is attached.

Active

What is the purpose of this research study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BAN2401, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called amyloid beta, in the brain. We hope that BAN2401 can reduce the amount of amyloid.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease dementia

-- are between the age of 50 and 90

Active

Our Research. Your Story.

Research is happening at Massachusetts General Hospital (MGH) that is focused on learning about the cognitive abilities, personality, and other traits of people who have more than one blood relative affected with Frontotemporal Degeneration (FTD), Alzheimer’s disease, and related disorders.

 

You Can Contribute to the Cause

Active

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.

 

We are looking for participants who:

-- do not have memory problem

-- are between age 65 and 85

-- have a reliable caregiver or family member who knows them well

-- are in stable medical condition

Active

Are you:

□ between the ages of 55-85?
□ able to have an MRI?
□ interested in participating in research?

 

The MassGeneral Institute for Neurodegenerative Disease (MIND) is seeking both healthy individuals and individuals with Mild Cognitive Impairment (MCI) or Dementia due to Alzheimer’s Disease to participate in a research study.

 

More information is attached.

Active

We're looking for adults with AD, FTD, MCI or cognitive complaints, ages 50-95!

 

The purpose of this research study is to look at brain connectivity in a variety of people with memory problems, including people with complaints about their memory and people diagnosed with a neurodegenerative disease, including Alzheimer’s disease (AD), fronto-temporal dementia (FTD), and mild cognitive impairment (MCI).

 

What to expect:

•     one 3-hour visit

Active

The purpose of this study is to determine the presence of the protein Tau in the brain in a variety of populations, ranging from healthy adults to those diagnosed with a neurodegenerative disease.

 

What to expect:

-- 8-month study

-- Memory testing

-- MRI scans

-- PET scans

-- Blood work

-- Optional:  Lumbar puncture

Active

What is DIAN?

DIAN stands for the Dominantly Inherited Alzheimer’s Network.  This international network has been established by the National Institute on Aging of the National Institutes of Health (US) to bring together researchers who study genetic forms of Alzheimer’s disease (AD). 

 

Syndicate content